Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07288190

Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR

To evaluate adherence to a single dual-prevention pill (DPP) compared with a two-pill regimen (2PR) for pre-exposure prophylaxis (PrEP) and pregnancy prevention in women without HIV.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

16 year–39 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Eswatini Prevention Center CRS, Mbabane, Eswatini

Loading trial locations.

About this study

To evaluate adherence to a single DPP consisting of co-formulated Tenofovir Disoproxil Fumarate and Emtricitabine (FTC/TDF) plus combined ethinyl estradiol/levonorgestrel oral contraceptive (COC), compared with a two-pill regimen (2PR) consisting of daily oral FTC/TDF pill and combined COC pill, for pre-exposure prophylaxis PrEP and pregnancy prevention in women without HIV.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 16 through 39 years old (inclusive) at Screening.
  • Adults must be able and willing to provide informed consent. Adolescents (16- and 17-year-olds) will be consented according to applicable local guidelines, by obtaining participant assent and where applicable parental or guardian permission.
  • Able and willing to provide adequate locator information.
  • Able and willing to comply with all study procedures.
  • Must be post-menarche and pre-menopausal and could potentially become pregnant.
  • Sexually active, defined as having had penile-vaginal sex within the 3 months before Screening (per self-report)
  • Negative pregnancy test at Screening and Enrollment.
  • Does not intend to become pregnant within the next 12 months.
  • Willing to use COCs for at least 48 weeks as their method of contraception.
  • HIV negative at Screening and Enrollment.
  • Willing to use oral PrEP for at least 48 weeks.
  • Hepatitis B (HBV) surface antigen (HbsAg) negative per blood test at Screening.
  • Hepatitis C (HCV) negative at Screening.
  • Normal estimated creatinine clearance (eCrCl) ≥ 60 ml/min per blood test at Screening.

Exclusion criteria

  • Intolerance, adverse reaction, or laboratory abnormality associated with PrEP use in the past.
  • Unable to become pregnant e.g., had a tubal ligation or hysterectomy or otherwise lacks a uterus, or is currently using another form of contraception.
  • Medically ineligible for combined hormonal contraception and specifically COCs per World Health Organization (WHO) medical eligibility criteria for contraceptive use or similar local medical eligibility guidelines (e.g., Centers for Disease Control and Prevention eligibility criteria).
  • Medically ineligible for PrEP based on WHO and/or local guidelines.
  • Using or planning to use another pregnancy prevention product other than oral contraception (condoms are permitted) during the next 48 weeks.
  • Using or planning to use another HIV prevention product other than condoms during the next 48 weeks.
  • Any other condition the clinician feels would jeopardize the health and wellbeing of the participant

Treatment and study plan

DPP

Drug

Daily, single, co-formulated, FTC/TDF + combined ethinyl estradiol/levonorgestrel oral contraceptive pill

2PR

Drug

Daily, two-pill regimen of oral FTC/TDF and ethinyl estradiol/levonorgestrel oral contraceptive pill

Free Choice

Drug

Choice of either DPP or 2PR

Primary outcomes

  1. PrEP adherence to DPP during randomized crossover period 1

    Time frame: Week 12

    Intraerythrocytic Tenofovir Diphosphate (TFV-DP) concentrations in dried blood spot (DBS)

  2. PrEP adherence to 2PR during randomized crossover period 1

    Time frame: Week 12

    Intraerythrocytic TFV-DP concentrations in DBS

  3. PrEP adherence to DPP during randomized crossover period 2

    Time frame: Week 24

    Intraerythrocytic TFV-DP concentrations in DBS

  4. PrEP adherence to 2PR during randomized crossover period 2

    Time frame: Week 24

    Intraerythrocytic TFV-DP concentrations in DBS

Secondary outcomes

  1. PrEP adherence to DPP during Choice period

    Time frame: Week 48

    TFV-DP concentrations in DBS

  2. PrEP adherence to 2PR during Choice period

    Time frame: Week 48

    TFV-DP concentrations in DBS

  3. PrEP adherence to DPP during Choice period

    Time frame: Week 48

    Self-reported adherence

  4. PrEP adherence to 2PR during Choice period

    Time frame: Week 48

    Self-reported adherence

  5. Acceptability of DPP during crossover period

    Time frame: Week 24

    Answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)

  6. Acceptability of 2PR during crossover period

    Time frame: Week 24

    Answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)

  7. Acceptability of DPP during Choice period

    Time frame: Week 48

    Answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)

  8. Acceptability of 2PR during Choice period

    Time frame: Week 48

    Acceptability of 2PR based on answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)

  9. Preference for DPP

    Time frame: Day 0

    Preference of DPP at enrollment

  10. Preference for DPP

    Time frame: Week 24

    Preference of DPP at completion of the crossover phase of the study

  11. Preference for 2PR

    Time frame: Day 0

    Preference of 2PR at enrollment

  12. Preference for 2PR

    Time frame: Week 24

    Preference of 2PR at completion of the crossover phase of the study

  13. PrEP persistence on DPP during the Choice period

    Time frame: Week 48

    Proportion of participants still using their chosen regimen at end of the Choice period

  14. PrEP persistence on 2PR during the Choice period

    Time frame: Week 48

    Proportion of participants still using their chosen regimen at end of the Choice period

  15. Overall tolerability of DPP

    Time frame: Week 48

    Tolerability

  16. Overall tolerability of 2PR

    Time frame: Week 48

    Tolerability

  17. Tolerability of DPP during the crossover period

    Time frame: Week 24

    Tolerability

  18. Tolerability of 2PR during the crossover period

    Time frame: Week 24

    Tolerability

  19. Tolerability of DPP during the Choice period

    Time frame: Week 48

    Tolerability

  20. Tolerability of 2PR during the Choice period

    Time frame: Week 48

    Tolerability

  21. Overall side effects of DPP

    Time frame: Week 48

    Grade 2+ Adverse Events (AE)

  22. Overall side effects of 2PR

    Time frame: Week 48

    Grade 2+ AE

  23. Side effects of DPP during the crossover period

    Time frame: Week 24

    Grade 2+ AE

  24. Side effects of 2PR during the crossover period

    Time frame: Week 24

    Grade 2+ AE

  25. Side effects of DPP during the Choice period

    Time frame: Week 48

    Grade 2+ AE

  26. Side effects of 2PR during the Choice period

    Time frame: Week 48

    Grade 2+ AE

  27. Overall unintended IPV of DPP

    Time frame: Week 48

    Intimate Partner Violence (IPV)

  28. Overall unintended IPV of 2PR

    Time frame: Week48

    IPV

  29. Unintended IPV of DPP during the crossover period

    Time frame: Week 24

    IPV

  30. Unintended IPV of 2PR during the crossover period

    Time frame: Week 24

    IPV

  31. Unintended IPV of DPP during the Choice period

    Time frame: Week 48

    IPV

  32. Unintended IPV of 2PR during the Choice period

    Time frame: Week 48

    IPV

  33. Overall unintended pregnancy of DPP

    Time frame: Week 48

    Pregnancy

  34. Overall unintended pregnancy of 2PR

    Time frame: Week 48

    Pregnancy

  35. Unintended pregnancy of DPP during the crossover period

    Time frame: Week 24

    Pregnancy

  36. Unintended pregnancy of 2PR during the crossover period

    Time frame: Week 24

    Pregnancy

  37. Compare unintended pregnancy of DPP during the Choice period

    Time frame: Week 48

    Pregnancy

  38. Compare unintended pregnancy of 2PR during the Choice period

    Time frame: Week 48

    Pregnancy

  39. Overall unintended HIV incidence of DPP

    Time frame: Week 48

    HIV incidence

  40. Overall unintended HIV incidence of 2PR

    Time frame: Week 48

    HIV incidence

  41. Unintended HIV incidence of DPP during the crossover period

    Time frame: Week 24

    HIV incidence

  42. Unintended HIV incidence of 2PR during the crossover period

    Time frame: Week 24

    HIV incidence

  43. Unintended HIV incidence of DPP during the Choice period

    Time frame: Week 48

    HIV incidence

  44. Unintended HIV incidence of 2PR during the Choice period

    Time frame: Week 48

    HIV incidence

Study contacts

Contact information is provided by the study sponsor or research team.

Michelle Robinson

CONTACT

[email protected]

919-321-3585

Scott Rose

CONTACT

[email protected]

919-321-3530

Sponsors and collaborators

Lead sponsor

HIV Prevention Trials Network

Network

Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

A Multisite, Open-label, Randomized Crossover Study Comparing Adherence to a Single Daily Dual Prevention Pill (DPP) Versus FTC/TDF and Combined Oral Contraception Separate Pill Dosing (2PR), Given for Pre-exposure Prophylaxis and Pregnancy Prevention in Women

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Dec 17, 2025
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.